Changing the delivery of immune-based cancer drugs could reduce costs by 14%

A new analysis finds that up to millions of dollars could be saved annually on cancer immunotherapy treatments across the Veterans Health Administration by reconsidering how those drugs are delivered. The study is published in Health Affairs.

Leave A Comment

Your email address will not be published. Required fields are marked *